MX2018009193A - Composición farmacéutica para prevenir o tratar nefropatía diabética. - Google Patents

Composición farmacéutica para prevenir o tratar nefropatía diabética.

Info

Publication number
MX2018009193A
MX2018009193A MX2018009193A MX2018009193A MX2018009193A MX 2018009193 A MX2018009193 A MX 2018009193A MX 2018009193 A MX2018009193 A MX 2018009193A MX 2018009193 A MX2018009193 A MX 2018009193A MX 2018009193 A MX2018009193 A MX 2018009193A
Authority
MX
Mexico
Prior art keywords
diabetic nephropathy
pharmaceutical composition
preventing
treating diabetic
inhibiting
Prior art date
Application number
MX2018009193A
Other languages
English (en)
Inventor
Han Kim Ji
Han Lee Joo
Original Assignee
Boryung Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59398368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018009193(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boryung Pharm filed Critical Boryung Pharm
Publication of MX2018009193A publication Critical patent/MX2018009193A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición farmacéutica de la presente invención puede prevenir o tratar de forma eficaz nefropatía diabética al: bloquear, inhibir o retrasar, con antelación, el inicio de la nefropatía diabética; o aliviar la nefropatía diabética o inhibir el progreso de la nefropatía diabética.
MX2018009193A 2016-01-27 2016-01-27 Composición farmacéutica para prevenir o tratar nefropatía diabética. MX2018009193A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2016/000898 WO2017131252A1 (ko) 2016-01-27 2016-01-27 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2018009193A true MX2018009193A (es) 2019-01-14

Family

ID=59398368

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009193A MX2018009193A (es) 2016-01-27 2016-01-27 Composición farmacéutica para prevenir o tratar nefropatía diabética.

Country Status (6)

Country Link
CO (1) CO2018008145A2 (es)
MX (1) MX2018009193A (es)
PH (1) PH12018501570A1 (es)
RU (1) RU2702117C1 (es)
SG (1) SG11201806292QA (es)
WO (1) WO2017131252A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
KR101810975B1 (ko) * 2010-07-08 2017-12-20 에스케이바이오팜 주식회사 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물
KR101414873B1 (ko) * 2012-06-28 2014-07-03 보령제약 주식회사 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물
KR20150041223A (ko) * 2013-10-04 2015-04-16 보령제약 주식회사 피마살탄을 포함하는 허혈성 뇌질환 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
WO2017131252A1 (ko) 2017-08-03
PH12018501570A1 (en) 2019-04-15
SG11201806292QA (en) 2018-08-30
CO2018008145A2 (es) 2018-10-31
RU2702117C1 (ru) 2019-10-04

Similar Documents

Publication Publication Date Title
PH12017501999A1 (en) K-ras modulators
EP3501527A4 (en) COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER, CONTAINING A VESICLE DERIVED FROM BACTERIA OF A SPECIES ACTOBACILLUS
PH12018501009A1 (en) Methods for treating conditions associated with masp-2 dependent complement activation
PH12015502091A1 (en) Cdc7 inhibitors
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
GB2541571A (en) Pharmaceutical compositions
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
TW201713333A (en) Methods of treating a neurodegenerative disease
PH12018550186A1 (en) Pharmaceutical combinations for treating cancer
IL254169B (en) A preparation for the prevention or treatment of valve calcification, containing a dpp-4 inhibitor
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
IL263697A (en) Compounds, preparations and methods for the treatment and/or prevention of cancer
MX2021006326A (es) Inhibidores de pcna.
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
EP3295946A4 (en) Composition, containing lithospermi radix extract as active ingredient, for preventing, alleviating, or treating peripheral neuropathy
IL269769B (en) Mixtures, composition and their use for cancer treatment
PH12018501570A1 (en) Pharmaceutical composition for preventing or treating diabetic nephropathy
IL282692A (en) Compounds derived from madrasin, a preparation and their uses for the treatment of cancer
EP3710003A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR SELECTIVELY INHIBITING BETA-GLUCURONIDASES AND ATTENUATING SIDE EFFECTS ASSOCIATED WITH DIARRHEA CAUSED BY DRUG TREATMENT
MX2019001425A (es) Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea.
BR112017016596A2 (pt) composição farmacêutica para prevenir ou tratar a leucemia mieloide crônica, e método de prevenção ou tratamento da leucemia mieloide crônica de um sujeito
GB2546703A (en) Compounds
NZ730759A (en) 1,2-benzothiazole compounds for the treatment of kidney disorders